Plasma Concentration of Biological Markers in Placental Abruption
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 1/9/2019 |
| Start Date: | March 2019 |
| End Date: | December 2020 |
| Contact: | Caesar A Guevara |
| Email: | CAGuevara@uams.edu |
| Phone: | 501-526-5879 |
This will be a prospective study conducted on women with a suspected/confirmed diagnosis of
placental abruption. Maternal blood samples will be taken at various points during the
peripartum period. A healthy group of women admitted for delivery will act as a matched
control and will have their blood sampled at similar time points. The primary outcome
variables will include the total number of micro-particles, the number of micro-particles
from each cell line (platelet, placental, endothelial etc.), and protein markers
(specifically; placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1),
vascular endothelial growth factor (VEGF), soluble endoglin (sEng)). Secondary outcomes if
will examine the correlation between placental micro-particles, biomarkers, and extent of
placental abruption.
placental abruption. Maternal blood samples will be taken at various points during the
peripartum period. A healthy group of women admitted for delivery will act as a matched
control and will have their blood sampled at similar time points. The primary outcome
variables will include the total number of micro-particles, the number of micro-particles
from each cell line (platelet, placental, endothelial etc.), and protein markers
(specifically; placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1),
vascular endothelial growth factor (VEGF), soluble endoglin (sEng)). Secondary outcomes if
will examine the correlation between placental micro-particles, biomarkers, and extent of
placental abruption.
The purpose of this study is to determine how well maternal serum biomarkers and placental
micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins
will be analyzed to further increase our understanding of the pathological mechanisms
involved in PA. The knowledge gained from this study has the potential to develop a
diagnostic test for PA with the ability to improve outcomes for mother and baby through
earlier diagnosis and targeted therapy.
micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins
will be analyzed to further increase our understanding of the pathological mechanisms
involved in PA. The knowledge gained from this study has the potential to develop a
diagnostic test for PA with the ability to improve outcomes for mother and baby through
earlier diagnosis and targeted therapy.
Inclusion Criteria:
- Age 18 - to 45-years old, inclusive
- Suspected or confirmed PA or phenotypically matched controls
- All modes of delivery
- Gestational age greater than 28 weeks
- Singleton pregnancy
Exclusion Criteria:
- Intrauterine fetal demise,
- Severe fetal anomalies (infant not expected to survive)
- Inability to communicate in English
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
